Release date: 2018-04-09
T cells (red) are attacking cancer cells (white). This new technology can be used to reduce the toxic side effects of T cell immunotherapy. |NIH Gallery / CC BY-NC 2.0
Kole Roybal became the winner of the first Sartorius & Science Prize for Regenerative Medicine & Cell Therapy in 2018 with its new T-cell immunotherapy. This new T-cell immunotherapy can be precisely adjusted to better assist the immune system. Cancer and play a precise therapeutic role in the disease. His research in the award-winning essay “Refining cell therapy†helps overcome the major obstacles that currently hinder the full potential of T-cell immunotherapy and provide patients with more favorable therapeutic effects.
The Sartorius & Science Prize was established in 2017 and is presented annually for researchers engaged in basic research or translational research. Participants are required to submit a 1,000-word research essay describing their research on regenerative medicine and cell therapy (including The impact of the field of cells, genes or immunotherapy, tissue engineering and materials engineering. The winner will receive a $25,000 award and publish the research essay on Science.
For most of the current T-cell immunotherapy, T cells (which play a central role in the defense of the body) recognize and destroy tumors, but their activity is not specifically regulated, so they may cause toxicity and adverse reactions due to inflammatory reactions, or cause Some patients have poor treatment results. Roybal said, "Immune cell therapy for cancer or autoimmune diseases (such as rheumatoid arthritis), if you want to safely and effectively replace more traditional drug therapies, we must be able to control the activity of these cells to reduce the patient Risk of toxicity".
In order to solve the above problems, Roybal (now an assistant professor at the University of California, San Francisco) and his colleague Leonardo Morsut turned their attention to a signal molecule on the T cell, the Notch receptor, which is considered to be involved in some Developmental and biological processes. Roybal concluded that Notch receptors may act as "sensors" to detect disease or tissue-specific signals and initiate more simplified individualized treatments. He developed a "single-single" synthesis of the Notch receptor (called synNotch), which can be tailored to the target disease and is expected to circumvent adverse reactions and focus treatment where it is most needed.
Roybal's award-winning paper was published in the March 9 issue of Science, highlighting the benefits of this new technology. He said, "Through the SynNotch receptor, we can basically limit the T cell response to the disease site, in order to enhance the ability of T cells, such as overcoming the unfavorable microenvironment of solid tumors. SynNotch engineered T cells also have many effects. It can be used to promote a potent immune response against cancer, as well as to suppress immune responses in autoimmune diseases."
Roybal said, "We can also edit these T cells to have functions that they didn't have. Our research shows that T cells can produce therapeutic substances such as antibodies in solid tumors. In principle, we hope to pass T Cells or other types of cells are engineered to persist in the body, producing therapeutic substances when they recognize a disease or relapse of the disease. This is very similar to the natural immune system we are always prepared to deal with infection."
Killer T cells surround cancer cells. |NIH Gallery / CC BY-NC 2.0
Priscilla Kelly, a biomedical editor at Science magazine, said, "Dr. Kole Roybal's research uses innovative techniques to improve the immune system to identify disease states. He discovered a molecular sensor that can be used to isolate human blood-derived T cells. Editors, based on custom-made methods of action to prevent T cell attacks. In principle, this synthetic switching mechanism can respond to cancer and autoimmune diseases, and may also respond to neurological and muscle cell diseases. Dr. Roybal Research has shown that cutting-edge science can bring cures to diseases that are currently difficult to treat."
Roybal mentioned that his team is working to develop synNotch T cells for clinical targets. The next step is to edit T cells to reliably detect multiple cancer features, such as mesothelioma and glioblastoma, to improve the accuracy of targeted diseases. He is also working to develop new receptors so that cell-treating substances can enter the disease site more efficiently and stay there during treatment. Roybal said, "This is especially beneficial for the treatment of solid tumors. Currently, T-cell therapies for solid tumors are mostly ineffective."
Science magazine editor Jeremy Berg said, "Science Magazine is pleased to work with Sartorius to recognize important research results in the rapidly growing field of regenerative medicine and cell therapy. These areas and new winners have witnessed How to use its decades of accumulation in basic biological mechanisms to develop new treatments."
Roybal and the following three finalists will be awarded the award ceremony on March 20th at the Alte Mensa Conference Center, University of Göttingen, Germany:
Shruti Naik, the award-winning paper "The healing power of painful memories". Naik holds a BA in Cell Molecular Biology from the University of Maryland, USA, and a Ph.D. in Immunology through the University of Pennsylvania-National Institute of Health Graduate Program. During her graduate studies, she discovered that normal bacteria on our skin train the immune system, protect us from harmful pathogens, and open the door to skin microbiota treatment. She is currently working on the interaction between immune cells and stem cells at Rockefeller University in the United States, working on stem cell therapies for inflammatory diseases. She is also an active advocate of women's participation in scientific research.
Fotios Sampaziotis, award-winning paper "Building better bile ducts". Sampaziotis graduated from the University of Athens, Greece with a medical degree. He also holds a Ph.D. in Stem Cell Biology from the University of Cambridge, England. During his Ph.D. study, he pioneered the use of bile duct-like organs to establish a model of the biliary system disease, tested multiple drugs, and discovered new therapeutic drugs. As a clinical lecturer in hepatology at the University of Cambridge in the UK, Fotios continues his research in the intersection of basic medicine and clinical medicine and conducts clinical work at Addenbrooke's Hospital. His research focuses on organ integration, bioengineering and animal research, rebuilding damaged bile ducts in the liver and providing alternative treatments for liver transplantation.
Will Mclean, award-winning paper "Towards a true cure for hearing impairment". During his undergraduate degree, McLean studied biology at Tufts University in the United States and later received his Ph.D. from the Harvard MIT Health Science and Technology Department at the Massachusetts Institute of Technology (MIT). His Ph.D. study at MIT clarified the existence of unique progenitor cell types in the inner ear that are capable of forming sensory and neural cells. During his postdoctoral research at Harvard Medical School, he studied the use of small molecule drugs to regulate signaling pathways to differentiate other aging cochlear progenitors and form new sensory cells. He is currently the Vice President of the Department of Biology and Regenerative Medicine at Frequency Therapeutics, a department that is using McLean's past experience to develop drugs that can treat damaged sensory cells and treat hearing impairment.
Sartorius Lab Instruments is a subsidiary of Sartorius AG, which is dedicated to providing quality laboratory equipment, high-end consumables and exceptional service. Its users come from research and quality assurance laboratories and academic fields in the pharmaceutical, chemical and food industries. Among the laboratory weighing technology, Sartorius ranks as the world's second largest equipment supplier and is a prominent player in the world's leading suppliers of consumables, pipettes and laboratory pure water systems.
This article was translated from AAAS News, the original link:
Https://
Source: Bio Valley
Brand computer chips, dual-frequency integrated circuits, cross-magnetic induction detection, bringing higher accuracy, reliability and stability. 2. Automatic control system, using special magnetic materials and unique technology, the detection accuracy of the probe is particularly high, and the accurate position of the broken needle is displayed in 8 detection areas. 3. Dual probe design, double detection function, higher safety performance, compared with other types of needle detectors, at the same detection height, the sensitivity is increased by 10%. 4. Automatic detection, automatic induction, automatic stop when no detection is needed, 0-10 sensitivity adjustment, when there is a broken needle, the conveyor belt automatically stops and returns backwards. 5. With a counting function, it can count the number of qualified or unqualified products. 6. It has two alarm modes: sound effect and light alarm. 7. Luxurious appearance, novel style, time-saving and power-saving, simple operation
Rapid PCR detection,Rapid Detection Rapid Detection PCR Kit Viral Antigen Detection
Jiangsu iiLO Biotechnology Co., Ltd. , https://www.sjiilogene.com